ERLINA PLUS XR 25/5/1000MG 14S
ERLINA PLUS XR 25/5/1000 mg Tab is an extended‑release (XR) antidiabetic medicine combining three proven glucose‑lowering agents — Empagliflozin 25 mg, Linagliptin 5 mg, and Metformin HCl 1000 mg XR — in a single, once‑daily tablet. This powerful triple combination helps manage type 2 diabetes mellitus more effectively by targeting multiple pathways of blood sugar control: improving insulin secretion, reducing glucose production, and increasing glucose removal from the bloodstream.
🧴 Active Ingredients
✔ Empagliflozin 25 mg – A SGLT2 inhibitor that increases the excretion of glucose through the kidneys.
✔ Linagliptin 5 mg – A DPP‑4 inhibitor that enhances insulin release after meals.
✔ Metformin HCl 1000 mg (XR) – A biguanide that reduces liver glucose production and increases insulin sensitivity.
🩺 Uses
• Management of Type 2 Diabetes Mellitus when diet and exercise alone are insufficient.
• Helps lower elevated blood glucose levels throughout the day with once‑daily dosing.
• Support in overall glycemic control to reduce the risk of diabetes‑related complications.
🌟 Benefits
✨ Triple‑mechanism glucose control — targets kidney, pancreas, and liver pathways simultaneously.
✨ Convenient once‑daily extended‑release formula for steady blood sugar management.
✨ May support cardiovascular benefits associated with better metabolic control (as described for components like empagliflozin).
✨ Improves insulin sensitivity and lowers glucose production.
⚠️ Possible Side Effects
Like all medications, ERLINA PLUS XR can cause side effects, including:
• Gastrointestinal discomfort: nausea, diarrhea, abdominal pain.
• Increased urination & thirst (from empagliflozin’s action).
• Genital or urinary tract infections (more common with SGLT2 inhibitors).
• Hypoglycemia (low blood sugar) especially if used with insulin or sulfonylureas.
• Rare but serious reactions: dehydration, ketoacidosis (call doctor immediately).
Precautions: Suitable for type 2 diabetes only; not for type 1 diabetes or diabetic ketoacidosis. Consult a healthcare provider before starting, especially in kidney or liver impairment.
🧠 How It Works
• Empagliflozin blocks glucose reabsorption in kidneys, increasing its excretion.
• Linagliptin prolongs incretin hormones to boost insulin release after meals.
• Metformin XR reduces liver glucose production and enhances insulin sensitivity. ✳ Together, these actions improve daily glucose control.
🏭 Manufacturer / Brand
Brand: Erlina Plus XR
Manufacturer: Pharmevo (Pvt.) Ltd. — a recognized pharmaceutical company producing antidiabetic agents in Pakistan.